Novo Nordisk A/S

Equities

NOVO B

DK0062498333

Pharmaceuticals

Market Closed - Nasdaq Copenhagen 16:20:00 19/07/2024 BST 5-day change 1st Jan Change
906.1 DKK +2.15% Intraday chart for Novo Nordisk A/S -7.57% +29.80%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Eli Lilly's weight loss drug tirzepatide gets approval in China RE
European Equities Traded in the US as American Depositary Receipts Trend Lower Friday; Set to End Week Down 4% MT
Eli Lilly's weight loss drug tirzepatide gets approval in China RE
NOVO NORDISK : Goldman Sachs maintains a Buy rating ZD
Health Care Drops as Novo Nordisk, Eli Lilly Slide - Health Care Roundup DJ
European Equities Traded in the US as American Depositary Receipts Trend Lower Thursday MT
Health Care Climbs as J&J Rallies - Health Care Roundup DJ
European Equities Traded in the US as American Depositary Receipts Fall in Wednesday Trading MT
Novo Nordisk to Update Weight Loss Drugs Labels Over EMA's Safety Recommendation MT
European shares slide as tech stocks weigh RE
Dutch government should not subsidise weight-loss drug Wegovy, adviser says RE
Roche reports positive early results in obesity drug trial RE
Dutch Health Care Wary of Reimbursing Novo Nordisk's Obesity Drug Cost MT
Novo Nordisk's Main Owner Leads $100 Million Financing of Biotech Firm Asceneuron DJ
Novo owner backs Swiss biotech Asceneuron in $100 million round RE
Health Care Declines on Regulatory Fears - Health Care Roundup DJ
European Equities Close Lower in Monday Trading; Luxury Goods Stocks Fall as Burberry Reports 'Disappointing' Q1 Results, Fires CEO MT
Novo Nordisk Says No Meeting Scheduled With US Senate Aides, Senior Executives MT
Novo Nordisk Reported to Meet Senate Staff Over Decision to Discontinue Levemir Insulin MT
Novo Nordisk Denies Reported Meeting with US Senate Aides Over Insulin Discontinuation MT
Novo Nordisk to Meet US Senate Aides Over Levemir Insulin Sales Halt MT
Novo Nordisk faces scrutiny on Capitol Hill for pulling Levemir insulin from US market RE
Ozempic linked with lower dementia risk, nicotine use, British study finds RE
European Equities Close Higher in Friday Trading; Unilever to Cut 3,200 European Jobs MT
EU Drug Regulator Issues New Safety Measures for GLP-1 Drugs Amid Aspiration Risk Concerns MT
Chart Novo Nordisk A/S
More charts
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows: - diabetes and obesity treatment products (92.6%); - rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc. Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
906.1 DKK
Average target price
964.6 DKK
Spread / Average Target
+6.45%
Consensus
  1. Stock Market
  2. Equities
  3. NOVO B Stock
  4. News Novo Nordisk A/S
  5. Novo Nordisk Plans First Bond Sale in 2 Years